

April 11, 2016



## VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series

NAMUR, Belgium, April 11, 2016 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today announced that its Chief Scientific Officer, Dr. Jake Micallef, will participate in a panel discussion at the Morgan Stanley Med Tech and Life Science Tools Insight Day, being held April 14 in New York, NY. The panel is entitled "Clinical Genomics: Is There an Inflection Ahead?" and will feature discussion of key trends and opportunities in the genomics market.

Details of the panel are as follows:

**Event** Morgan Stanley Med Tech and Life Science Tools Insight Day  
**Date** Thursday, April 14, 2016  
**Time** 11: 00 a.m. EDT

The event, part of the broader Morgan Stanley Healthcare Insight Series being held April 12-14, will feature a series of panel discussions in which representatives of private and public companies, industry experts and consultants will discuss the current state of key markets in the orthopedics, cardiovascular and diagnostics sectors.

### About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The NuQ<sup>®</sup> tests are based on the science of Nucleosomics<sup>®</sup> which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website ([www.volitionrx.com](http://www.volitionrx.com)) or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

An animation introducing VolitionRx's Nucleosomics<sup>®</sup> technology can be found at: <https://www.youtube.com/watch?v=38dodCpyXf0>.

### Media Contacts

Anita Heward, VolitionRx  
[a.heward@volitionrx.com](mailto:a.heward@volitionrx.com)  
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group  
[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)  
Telephone: +1 (508) 280-6592

### **Investor Contacts**

Scott Powell, VolitionRx  
[S.Powell@volitionrx.com](mailto:S.Powell@volitionrx.com)  
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)  
Telephone: +1 (646) 536-7012

### **Safe Harbor Statement**

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics<sup>®</sup>, NuQ<sup>®</sup> and HyperGenomics<sup>®</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-to-participate-in-2016-morgan-stanley-healthcare-insight-series-300249055.html>

SOURCE VolitionRx Ltd